Remarkably, mouse experiments unambiguously revealed that the medium dose of neratinib not only retained its potential to enhance the efficacy of CDK4/6 inhibitor combined with endocrine therapy in HR+/HER2-low breast cancer but also had good tolerability (P < 0.001). Here, ERBB2 is linked to breast carcinoma.